DOI:
10.1055/s-00000134
Diabetologie und Stoffwechsel
LinksClose Window
References
Rosenstock J, Perkovic V, Alexander JH. et al
Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
Cardiovasc Diabetol 2018;
17: 39 . doi:10.1186/s12933-018-0682-3
Access:
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.